Denmark Novo Nordisk - Search News

Novo Nordisk to cap insulin prices in Minnesota settlement

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

MinnPost · 1d

AG Ellison settles with Novo Nordisk to cap out-of-pocket payments for insulin at $35 a month

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.

Reuters · 1d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

KARE-TV Minneapolis-St. Paul o… · 1d

Novo Norodisk caps insulin prices at $35 for Minnesotans

If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.

Novo Nordisk’s Ozempic Gets FDA Approval

U.S. News & World Report · 3h

US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease

(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

Hosted on MSN · 3h

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Reuters · 3h

US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression

Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes.

12d

Novo Nordisk, other firms meet Danish PM to discuss Trump tariff threats

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

4don MSN

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

10h

UBS Remains a Buy on Novo Nordisk (0QIU)

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

PharmiWeb1d

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Novo Nordisk A/S - share repurchase programme

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

11don MSN

Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

1don MSN

Jim Cramer on Novo Nordisk (NVO): ‘Be Careful’ Amid Trump Impact

Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results